Chroma Medicine and Nvelop Therapeutics, two biotechnology companies, have merged to form nChroma, which aims to advance research and therapy development in the field of genetic medicine. The agreement is intended to increase the range of diseases which can be treated by combining epigenetic editing plus non-viral programmable delivery.

nChroma has recently completed a financing round, securing $75 million in capital to fund the generation of clinical data and a pipeline of novel hepatic and extrahepatic targeted therapies. The financing round was led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners, with participation from a wide range other top tier investors.